4th Alpine Winter Conference on Medicinal and Synthetic Chemistry

 St. Anton, Austria    January 28-February 1, 2024

Keynote Speakers

New Catalytic Approaches for Simplifying Complex Molecule Synthesis (KL01)

Prof. Darren J. DIXON
Prof. Darren J. DIXON
UNIVERSITY OF OXFORD, Oxford, United Kingdom
Read more

The Discovery of PAXLOVID (KL02)

Dr Dafydd OWEN
Dr Dafydd OWEN
PFIZER, Cambridge, United States

Site-Selective C—H Oxidations for Late-Stage Functionalizations (KL03)

Prof. M. Christina WHITE
Prof. M. Christina WHITE
UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN, Urbana, United States
Read more

From Underground to Mainstream: Neglected and Novel, Emerging Functional Groups for Drug Discovery

Boron Based Heterocycles and their Application in Drug Discovery (PL05)

Prof. Bhaskar DAS
Prof. Bhaskar DAS
LONG ISLAND UNIVERSITY, Brooklyn, United States
Read more

“Magic Chloro”: Profound Effects of the Chlorine Atom in Drug Discovery (PL06)

Dr Yoshihiro ISHIHARA
Dr Yoshihiro ISHIHARA
VIVIDION THERAPEUTICS, San Diego, United States
Read more

Deuterium in Drug Design: From Deuterium Switch to De Novo Drug Discovery (PL07)

Prof. Tracey PIRALI
Prof. Tracey PIRALI
UNIVERSITY OF PIEMONTE ORIENTALE, Novara, Italy
Read more

New Functional Groups for Synthetic and Discovery Chemistry (PL08)

Prof. Michael WILLIS
Prof. Michael WILLIS
UNIVERSITY OF OXFORD, Oxford, United Kingdom
Read more

Human Dose Prediction in the Discovery Space

Early Human Dose Predictions in Lead Optimization (PL13)

Dr Johan BYLUND
Dr Johan BYLUND
CTC CLINICAL TRIAL CONSULTANTS AB, Uppsala, Sweden
Read more

Predicting Human Exposure and Dose of Compounds Targeting the Brain (PL16)

Dr Nicola COLCLOUGH
Dr Nicola COLCLOUGH
ASTRAZENECA, Cambridge, United Kingdom
Read more

Early Human Dose Prediction & Machine Learning Models - Can We Impact Lead Selection? (PL14)

Dr Gregori GEREBTZOFF
Dr Gregori GEREBTZOFF
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland
Read more

SwiftPK: Development and Implementation of a High Throughput PBPK/PD Framework to Inform Drug Selection in Early Drug Discovery (PL15)

Dr Andres OLIVARES
Dr Andres OLIVARES
F. HOFFMANN-LA ROCHE, Basel, Switzerland
Read more

Radical Intermediates in Complex Molecule Synthesis

Recent Adventures in Catalysis and Beyond (PL22)

Prof. Bill MORANDI
Prof. Bill MORANDI
ETH ZÜRICH, Zürich, Switzerland
Read more

Alkenes as Flexible Platforms for Asymmetric Transformations (PL23)

Prof. Cristina NEVADO
Prof. Cristina NEVADO
UNIVERSITY OF ZURICH, Zurich, Switzerland
Read more

Light-Mediated Nickel Catalysis Enabled by Donor-Acceptor Ligands (PL21)

Prof. Bart PIEBER
Prof. Bart PIEBER
INSTITUTE OF SCIENCE AND TECHNOLOGY AUSTRIA (ISTA), Klosterneuburg, Austria
Read more

Attempts to Deliver on the Promise of Natural Product Synthesis (PL24)

Prof. Ryan SHENVI
Prof. Ryan SHENVI
SCRIPPS RESEARCH, La Jolla, United States
Read more

Cryo-EM: Applications for Structure-Based Drug Discovery

Deep Learning-Driven De Novo Drug Design Based on Gastric Proton Pump Structure (PL25)

Prof. Kazuhiro ABE
Prof. Kazuhiro ABE
NAGOYA UNIVERSITY, Nagoya, Japan
Read more

Cryo-EM Enables Structure-Based Drug Design for Membrane Protein Targets at BI (PL26)

Dr Rebecca EBENHOCH
Dr Rebecca EBENHOCH
BOEHRINGER INGELHEIM, Biberach, Germany
Read more

Single Particle CryoEM at 200 kV & Itchy GPRCs (PL27)

Prof. Jonathan F. FAY
Prof. Jonathan F. FAY
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL, Chapel Hill, United States
Read more

Examples from Structure-Based Drug Discovery Using Cryo-EM at MSD (PL28)

Dr Harini KRISHNAMURTHY
Dr Harini KRISHNAMURTHY
MERCK, SHARP & DOHME, Blue Bell, United States
Read more

Recent Developments in Synthetic Methodologies and their Impact

Organic Reactions in Aqueous Medium enabled by Surfactants (PL01)

Dr Niginia BORLINGHAUS
Dr Niginia BORLINGHAUS
UNIVERSITY OF KONSTANZ, Konstanz, Germany
Read more

Reagents and Catalysts with Translational Potential (PL02)

Dr Josep CORNELLA COSTA
Dr Josep CORNELLA COSTA
MAX PLANCK INSTITUTE FOR COAL RESEARCH, Mülheim an der Ruhr, Germany
Read more

From Batch to Flow: Advancing Synthetic Organic Chemistry through Technological Innovation (PL03)

Prof. Timothy NOËL
Prof. Timothy NOËL
UNIVERSITY OF AMSTERDAM, Amsterdam, The Netherlands
Read more

Chemo-Biocatalytic Processes Enabled by a Continuous Flow Set Up (PL04)

Prof. Francesca PARADISI
Prof. Francesca PARADISI
UNIVERSITY OF BERN, Bern, Switzerland
Read more

Antiviral Drug Discovery

Discovery, Chemistry, and Preclinical Development of Pritelivir, a Novel Option for Acyclovir-Resistant Herpes Simplex Virus Infections (PL17)

Dr Alexander BIRKMANN
Dr Alexander BIRKMANN
AICURIS ANTI-INFECTIVE CURES AG, Wuppertal, Germany
Read more

Targeting Viral RNA Degradation Via Small Molecules As a Novel Antiviral Strategy to Achieve HBV Cure (PL18)

Dr Dimitar GOTCHEV
Dr Dimitar GOTCHEV
ARBUTUS BIOPHARMA, Doylestown, United States
Read more

Discovery of Obeldesivir; Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green Monkeys (PL20)

Dr Rao KALLA
Dr Rao KALLA
GILEAD SCIENCES, Foster City, United States
Read more

Direct-Acting Antivirals with a Targeted Protein Degradation Mechanism (PL19)

Prof. Priscilla YANG
Prof. Priscilla YANG
STANFORD UNIVERSITY, Stanford, United States
Read more

Latest Advances and Approaches in Bioconjugation Drug Discovery

Next-Generation Bioconjugates for Intra- and Extracellular Targeting (PL10)

Prof. Christian HACKENBERGER
Prof. Christian HACKENBERGER
FMP BERLIN, Berlin, Germany
Read more

Bicyclic Peptides as a Novel Therapeutic Modality (PL09)

Dr Philip MURRAY
Dr Philip MURRAY
BICYCLE THERAPEUTICS, Cambridge, United Kingdom
Read more

Creating Next-Generation Biotherapeutics Using Novel Chemistry Platform Technologies (PL11)

Dr Vijaya R. PATTABIRAMAN
Dr Vijaya R. PATTABIRAMAN
BRIGHT PEAK THERAPEUTICS, Basel, Switzerland
Read more

Exploring the Versatility of Covalent and Supramolecular Bioconjugation in ADC and AOC (PL12)

Dr Alain WAGNER
Dr Alain WAGNER
CNRS/UNIVERSITY OF STRASBOURG, Illkirch, France
Read more

Drug Discovery Tales I

Selective Inhibition of Tead Transcription and Impact on the Up-Stream Effector Kinases of the Hippo Pathway to Halt Metastatic Colorectal Cancer Cell Growth (OC05)

Prof. Maria Paola COSTI
Prof. Maria Paola COSTI
UNIVERSITY OF MODENA AND REGGIO EMILIA, Modena, Italy
Read more

Discovery of [18F]RoSMA-18-D6 for PET Imaging of Cannabinoid Type 2 Receptors (OC04)

Dr Luca GOBBI
Dr Luca GOBBI
F. HOFFMANN-LA ROCHE, Basel, Switzerland
Read more

Discovery of a Bivalent Protein Kinase CK2 Inhibitor with Activity in Renal Cell Carcinoma (OC02)

Dr Isabelle KRIMM
Dr Isabelle KRIMM
CLB, Lyon, France
Read more

Discovery of BI 7446: A Potent Cyclic Dinucleotide Sting Agonist with Broad-Spectrum Variant Activity for the Treatment of Cancer (OC03)

Dr Christian KUTTRUFF
Dr Christian KUTTRUFF
BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, Biberach, Germany
Read more

NLRP3 Inhibitors for Neurodegenerative Disorders (OC01)

Dr Oscar MAMMOLITI
Dr Oscar MAMMOLITI
JANSSEN RESEARCH & DEVELOPMENT, Beerse, Belgium
Read more

Drug Discovery Tales II

Discovery of a Novel Oral NO- and Heme-Independent sGC Activator Runcaciguat (BAY 1101042) (OC06)

Dr Michael G. HAHN
Dr Michael G. HAHN
BAYER AG PHARMACEUTICALS, Wuppertal, Germany
Read more

Discovery of LY3154885, a Dopamine D1 Receptor Positive Allosteric Modulator with an Improved Drug-Drug Interaction Risk Profile (OC09)

Dr Erik HEMBRE
Dr Erik HEMBRE
ELI LILLY AND COMPANY, Indianapolis, United States
Read more

Heterocyclic Compounds as Delta-5 Desaturase Inhibitors (OC07)

Dr Ana MINATTI
Dr Ana MINATTI
AMGEN INC, Copenhagen, Denmark
Read more

Novel Approaches to Molecular Glue Discovery: Design of Clinical Candidate NVP-DKY709 an IKZF2 Degrader by Re-Programming of CRBN Selectivity and Screening for Cooperativity Using DNA Encoded Libraries (OC8)

Dr Frédéric ZECRI
Dr Frédéric ZECRI
NOVARTIS, Cambridge, United States
Read more